Lung cancer immune markers under the microscope

NCT ID NCT07150598

Not yet recruiting Knowledge-focused Sponsor: Technische Universität Dresden Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This observational study aims to understand how the immune system and tumor markers relate to treatment response in 500 people with advanced non-small cell lung cancer. Participants will provide tumor samples before and during immunochemotherapy. The study does not test any new drug or treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better predict which lung cancer treatments work best for individual patients.
What could go wrong: This is an early observational study, not a treatment trial. It may not lead to immediate changes in patient care, and results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) NSCLC (NON-SMALL CELL LUNG CANCER) NSCLC STAGE IIIB~IV

Contacts and locations

Locations

Universitätsklinikum Carl Gustav Carus

Dresden, Saxony, 01307, Germany
Universitätsklinikum Köln, Centrum für Integrierte Onkologie (CIO) Köln

Cologne, North Rhine-Westphalia, 50937, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.